Veracyte, Inc.
@Veracyte
Followers
1K
Following
160
Statuses
1K
We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer.
Joined May 2010
Today, we stand with millions worldwide in the fight against cancer and re-emphasize our commitment to transform cancer care, and advance global access to our diagnostics tests to support physicians and patients in their cancer diagnosis journey. #WorldCancerDay
0
2
4
We honor Dr. Martin Luther King Jr.'s powerful legacy of justice and equality, including his passionate advocacy for healthcare access for all. May his vision continue to drive meaningful change ensuring medical breakthroughs reach every community through research and care.
0
0
0
American Cancer’s annual report highlights encouraging progress as well as ongoing challenges in our fight against cancer, emphasizing the importance of screening, early detection, and personalized medicine. Learn more about the role of genomic testing:
0
1
1
UroToday has launched a Center of Excellence for Decipher Prostate, featuring insights from #prostatecancer experts on using #DecipherProstate to help guide treatment decisions. 🎥Explore engaging videos, abstracts, and more.
0
2
1
We are grateful to have had the opportunity to work with @felixfengmd on innovative trials and biomarker development. His impact to cancer patients was profound and will be long lived. He will be dearly missed. #ProstateCancerResearch #CancerResearch #Healthcare #Innovation
1
1
8
Join us today at #SABCS24! Medical discussions at our Booth 1243 will feature valued customers Dr. Tomás Pascual and Brigitte Schober presenting #Prosigna-based trial designs in personalized therapy & an analysis of gene expression tests for #BreastCancer
0
2
2
Today at #SABCS24, we’re welcoming Dr. Francesco Schettini, Dr. Rodrigo Sánchez-Bayona, and Prof. Melissa Troester to offer expertise on intrinsic subtypes, use of #Prosigna in a tertiary hospital, and impact of #genomicassays in diverse populations.
0
2
4
Today at #SABCS24, join our valued customers from #IEO and #CambridgeUniversity as they present insights into our #ProsignaBreastCancerAssay’s impact on risk stratification and how Prosigna is being incorporated in the UK. Booth 1243. #oncology
0
1
4
Breaking: #Decipher Prostate is now the only gene expression test listed as an advanced tool in NCCN® Guidelines for risk stratification of localized prostate cancer. Validated in 100K+ patients, its the most validated test of its kind in #prostatecancer.
0
1
2
The VANDAAM trial assessed genomic prostate cancer risk-stratification in African American men and showed #DecipherProstate could play a role in reducing outcome disparities, offering more equitable #prostatecancer care. #MensHealthAwarenessMonth
0
2
1
Data from an analysis of the STAMPEDE trial highlights the important role of #DecipherProstate to provide clinicians with insights that can help ensure their patients receive the therapy they need and is right for them. Read more #MensHealthAwarenessMonth
0
2
3
It's #MensHealthAwarenessMonth and in this article, our CMO, Dr. Phillip G. Febbo, offers insights into the evolution of #prostatecancercare, the future role of #genomictesting, and the use of personalized-medicine tools, such as #DecipherProstate.
0
0
0
Today, our executive team showed their appreciation in style serving up a breakfast celebration for the SD crew. A heartfelt thank you in recognition of everyone’s hard work and achievements in our unwavering dedication to advance cancer care. #LifeAtVeracyte #TeamAppreciation
0
0
0
Veracyte today released our financial results for the third quarter of 2024. For the full press release and more Veracyte news, visit our press release page:
0
2
3
Did you know? Nearly 300K U.S. men face #ProstateCancer this year. Our #DecipherProstate genomic tests are empowering healthcare providers with clinical evidence for personalized treatment decisions. Learn more⬇️ #MensHealthMonth #movember2024
0
2
0
New article about #DecipherProstate & the Phase III, multi-center, randomized STAMPEDE clinical trial, offering insights into how our test is demonstrating to be the first molecular biomarker to predict #docetaxel sensitivity in advanced #prostatecancer.
0
4
2
Don’t miss this insightful poster presentation at #2024ATA by Julio Ricarte-Filho, PhD, Children's Hospital of Philadelphia - Distinct Molecular Profiles of Thyroid Nodules in Patients Under 21 Years of Age. Today at 10:15-11:15am CDT - POSTER: 0263. Visit Afirma at Booth 401!
0
1
0
At #2024ATA, don’t miss our poster presentation: Polyamine and Methionine Metabolism Gene Expression Analysis in Thyroid Tumors, with Cody Huffman, MS, Washington University School of Medicine. Today at 10:15 -11:15am CDT - POSTER: 0260. Visit Afirma at Booth 401! @washumedicine
0
1
0